

Human SETD7 Protein

Cat. No. SED-HM107



Description

Source	Recombinant Human SETD7 Protein is expressed from E.coli with His tag at the N-Terminus. It contains Met1-Lys366.
Accession	NP_085151.1
Molecular Weight	The protein has a predicted MW of 41.68 kDa. The protein migrates to 47-50 kDa based on Tris-Bis PAGE result.
Endotoxin	Less than 1EU per µg by the LAL method.
Purity	> 95% as determined by Tris-Bis PAGE > 95% as determined by HPLC

Formulation and Storage


Formulation	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -20 to -80°C for 3-6 months in unopened state after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

SETD7 is a methyltransferase that specifically catalyzes the monomethylation of lysine 4 on histone H3. A variety of studies has revealed the role of SETD7 in posttranslational modifications of non-histone proteins. Aberrant expression of SETD7 has been associated with various diseases, including cancer. As a prognostic marker of breast cancer and a novel antioxidant promoter under oxidative stress in breast cancer, SETD7 is considered a good target for the development of new epigenetic drugs.


Assay Data

Tris-Bis PAGE



Human SETD7 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC



The purity of Human SETD7 is greater than 95% as determined by SEC-HPLC.